FDA as a catalyst for translation

Science Translational Medicine

Volumn 7, Issue 296, 2015, Pages

  Calif, Robert M ^a   Ostrof, Stephen ^a  

^a CENTER FOR DRUG EVALUATION AND RESEARCH   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

BIOLOGICAL MARKER;

ACCESS TO INFORMATION; CATALYST; CLINICAL ASSESSMENT; CLINICAL DECISION MAKING; DIAGNOSTIC IMAGING; DIAGNOSTIC VALUE; DRUG SAFETY; EDITORIAL; FOOD AND DRUG ADMINISTRATION; HEALTH CARE PLANNING; HEALTH CARE POLICY; HUMAN; INTERNATIONAL COOPERATION; MINIMALLY INVASIVE PROCEDURE; NONHUMAN; OUTCOME ASSESSMENT; PATIENT PREFERENCE; PHENOTYPE; PRIORITY JOURNAL; PRODUCT SAFETY; PROFESSIONAL KNOWLEDGE; PUBLIC HEALTH SERVICE; RANDOMIZED CONTROLLED TRIAL (TOPIC); RISK ASSESSMENT; RISK BENEFIT ANALYSIS; SYSTEMS BIOLOGY; TRANSLATIONAL RESEARCH; UNITED STATES; CLINICAL TRIAL (TOPIC); DECISION MAKING; DRUG APPROVAL; ORGANIZATION AND MANAGEMENT; PATIENT SAFETY; TRENDS;

CLINICAL TRIALS AS TOPIC; DECISION MAKING; DRUG APPROVAL; HUMANS; PATIENT SAFETY; PHENOTYPE; SYSTEMS BIOLOGY; TRANSLATIONAL MEDICAL RESEARCH; UNITED STATES; UNITED STATES FOOD AND DRUG ADMINISTRATION;

EID: 84937110812     PISSN: 19466234     EISSN: 19466242     Source Type: Journal    
DOI: 10.1126/scitranslmed.aab2404     Document Type: Editorial

References (8)

1. FDA science and mission at risk: Report of the subcommittee on science and technology (November 2007); available at www.fda. gov/ohrms/dockets/AC/07/briefng/2007-4329b-02-01-FDA%20Report%20on%20Science%20and%20Technology.pdf.
2. Advancing regulatory science at FDA: A strategic plan (August 2011); available at www.fda.gov/downloads/ScienceResearch/ SpecialTopics/RegulatoryScience/UCM268225.pdf.
3. F. S. Collins, H. Varmus, A new initiative on precision medicine. N. Engl. J. Med. 372, 793-795 (2015).
4. st Century Cures: A Call to Action (U.S. House of Representatives Energy and Commerce Committee, Washington, DC, 2014); available at http://energycommerce.house.gov/sites/republicans.energycommerce.house.gov/fles/analysis/ 21stCenturyCures/20140501WhitePaper.pdf.
5. Biomarkers defnitions working group, Biomarkers and surrogate endpoints: Preferred defnitions and conceptual framework. Clin. Pharmacol. Ther. 69, 85-95 (2001).
6. Perspectives on biomarker and surrogate endpoint evaluation, Institute of Medicine report (National Academies Press, Washington, DC, 2011); available at www.iom.edu/Reports/2011/Perspectives-on-Biomarker-and-Surrogate-Endpoint-Evaluation.aspx.
7. ClinicalTrials.gov, Downloading content for analysis; available at www.clinicaltrials.gov/ct2/resources/download.
8. FDA's Sentinel Initiative, Transforming how we monitor the safety of FDA-regulated products; available at www.fda.gov/Safety/FDAsSentinelInitiative/ucm2007250.htm.